Recombinant factor VIIa: new insights into the mechanism of action through product innovation

Recombinant factor VIIa: new insights into the mechanism of action through product innovation

Management of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa). Two rFVIIa products are commercially approved for use in the United States and the European Union. Eptacog alfa and eptacog beta share the s...

Full description

Bibliographic Details
Main Authors: Miguel A. Escobar, Maureane Hoffman, Giancarlo Castaman, Cedric Hermans, Johnny Mahlangu, Johannes Oldenburg, Charles L. Percy, Mark T. Reding, Amy D. Shapiro, Steven W. Pipe
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
blood platelets
endothelial protein C receptor
factor VIIa
hemophilia A
hemophilia B
hemostasis
Online Access:http://www.sciencedirect.com/science/article/pii/S2475037924003650

Internet

http://www.sciencedirect.com/science/article/pii/S2475037924003650

Similar Items